Brad Bolzon, Ph.D. is the leader of the firm, architect of its strategy, and oversees operations across North America and Europe. Brad combines 13 years of global pharmaceutical industry leadership experience and 18 years as a venture capitalist. His track record consists of a multitude of successful investments including Amira, Okairos, Speedel, Quanticel, Novira, Flexion, Crispr, BioTie, Jecure, BlueRock, Black Diamond, Northern Biologics, Monte Rosa and the firm’s Discovery Engines that have collectively generated close to $1.7 billion in returns for Versant stakeholders. Over his tenure, he has translated that experience into building and developing the current Versant investment team.
Location
Menlo Park, California
Notable investments
No items found.
Check size range(s)
$0 - $100K
$100K - $500K
$500K - $1M
$1M - $3M
$3M - $10M
Rounds their fund invests in
Series A
Rounds their fund leads
No items found.
Sectors their fund invests in
Biotech
Geographies their fund invests in
USA
Canada
Europe
Browse through a massive startup database
Browse Harmonic, our favorite resource for parsing through the world's startup data.
Partner
Learn more about Harmonic
No items found.
No colleagues here yet.
Funds they're a part of
Versant Ventures
About the Fund
Provides state-of-the-art laboratories to launch novel biotech companies with academic founders.
View Profile
Their Colleagues
Sheets Their fund(s) are in
Is this you? Have any edits?
Fill out our update request form and we'll update ASAP
Related Investors
Round-focused Sheets
Geography-focused Sheets
Sector-focused Sheets
